Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bn
pharmaceutical-technology | February 17, 2017
Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn. The acquisition was concluded through a tender offer and subsequent merger of ARIAD with Takeda Pharmaceuticals USA’s wholly owned subsidiary Kiku Merger.